#1 Clinical Trials Search in Europe

A study of PF-08634404, ipilimumab, and axitinib in adults with advanced or metastatic kidney cancer

1 1 1

What is this study about?

This study is being conducted to evaluate the safety and effectiveness of the drug PF-08634404 when used alone or in combination with other medicines for adults with Renal Cell Carcinoma. This disease is a type of kidney cancer that is either locally advanced, meaning it has grown into nearby tissues, or metastatic, which means the cancer has spread to other parts of the body.

Participants may receive PF-08634404 through an intravenous method, which involves delivering the medicine directly into a vein. Depending on the assigned group, the treatment may also include ipilimumab, given by intravenous use, or axitinib, which is taken as an oral medication by mouth. The study involves testing these different combinations to see how well they work against the cancer and to identify the best amount of medicine to use.

Who Can Join the Study?

  • You must be 18 years of age or older at the time of the initial screening.
  • You must have locally advanced kidney cancer, which means the cancer is advanced but cannot be removed with surgery or treated with radiation, or metastatic renal cell carcinoma, which is a type of kidney cancer that has spread to other parts of the body.
  • Your diagnosis must be confirmed by histology or cytology, which means a doctor has looked at your cells under a microscope to confirm the cancer type.
  • You must have at least one measurable lesion, which is a tumor or area of cancer that is large enough for doctors to see and track using medical imaging.
  • The lesion must be untreated, meaning it has not been targeted by previous treatments.
  • You must have adequate hematologic, hepatic, cardiac, and renal function, which means your blood counts, liver, heart, and kidneys must be working well enough to participate safely.
  • You must not have received any prior systemic therapy for kidney cancer, which refers to treatments like drugs that travel through the entire body. However, you may have received immunotherapy (a treatment that helps your immune system fight cancer) after surgery if it was more than 12 months ago.
  • You must have an ECOG performance status of 0 or 1, which is a scale used by doctors to measure how well you can perform daily activities and how much the cancer affects your physical functioning.
  • You may fall into any IMDC risk category, which is a classification system used to group patients based on certain health factors to predict how the disease might progress.

Who Cannot Join the Study?

  • Having known active brain lesions, which means areas of cancer growth in the brain, including cancer that has spread to the brain lining (leptomeningeal metastasis), the brainstem, the protective layers around the brain (meninges), or the spinal cord, or any pressure on these areas.
  • Having any acute, chronic, or symptomatic infections, which refers to any current or long-term illnesses caused by germs like bacteria or viruses that are causing symptoms.
  • A history of immunodeficiency, which is a condition where your body’s immune system—the system that fights off germs—is not working correctly.
  • Having a high risk of haemorrhage (severe bleeding) or a fistula (an abnormal tunnel or connection that forms between two body parts).
  • Having a history of another malignancy, which is another word for cancer, within the last 3 years.
  • A history of allogeneic organ transplantation (receiving an organ from another person) or allogeneic hematopoietic stem cell transplantation (receiving blood-forming stem cells from another person).
  • Having active autoimmune diseases, which are conditions where the immune system mistakenly attacks the body’s own healthy cells, that required systemic treatment (medicine that travels through the whole body) within the last 2 years.
  • Having uncontrolled cardiac (heart) issues or other comorbidities (other medical conditions occurring at the same time) within 6 months before the first dose.
  • Having had major surgery or severe trauma (serious physical injury) within 4 weeks before the first dose, or having a major surgery planned during the study.
  • A history of severe bleeding tendency or coagulation dysfunction, which means your blood has trouble clotting or stopping a bleed.
  • A history of oesophageal varices (swollen veins in the tube connecting the throat to the stomach), severe ulcers (sores in the lining of the stomach or intestines), gastrointestinal perforation (a hole in the stomach or intestines), abdominal fistula (an abnormal connection in the belly area), gastrointestinal obstruction (a blockage in the digestive tract), or an intra-abdominal abscess (a collection of pus inside the belly).

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Hospital Clinico San Carlos Madrid Spain
Universitaetsklinikum Heidelberg AöR Heidelberg Germany
Technische Universitaet Dresden Dresden Germany

Other Sites

Site Name City Country Status
Hospital Universitario 12 De Octubre Madrid Spain
Charite Universitaetsmedizin Berlin KöR Berlin Germany
Hospital Universitario Fundacion Jimenez Diaz Madrid Spain
Hospital Universitario Virgen De La Victoria Malaga Spain
Uwrfnljaxzymyzuvfehjw Etrzc Azv Essen Germany
Hnvovltd Do Ls Skkfs Csqu I Sqmr Pjq Barcelona Spain
Hoadtdrr Vurx dvmdudcy Barcelona Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Germany Germany
Not yet recruiting
05.06.2026
Spain Spain
Not yet recruiting
05.06.2026

Trial locations

Investigated drugs:

Ipilimumab is a type of immunotherapy that helps the body’s own immune system recognize and attack cancer cells.

Axitinib is a targeted therapy medication that works by blocking certain proteins that help cancer cells grow and spread.

PF-08634404 is an experimental drug being studied to see how well it can fight cancer cells, both on its own and when used together with other cancer treatments.

Advanced or metastatic renal cell carcinoma – This is a type of cancer that starts in the cells of the kidney. The disease occurs when abnormal cells grow uncontrollably within the kidney tissue. In the advanced stage, the cancer has grown significantly within the kidney. When it becomes metastatic, the cancer cells spread from the kidney to other parts of the body, such as the lungs or bones. This progression involves the movement of malignant cells through the blood or lymphatic system.

Trial ID:
2025-523524-53-00
Protocol code:
C6461008
NCT ID:
NCT07227415
Trial Phase:
Human Pharmacology (Phase I) – Other

Other Trials to Consider

  • Belzutifan and Zanzalintinib in Adults with Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy

    Recruiting

    1 1 1
    Investigated drugs:
    Czechia Denmark France Germany Greece Italy +3

  • A study of belzutifan and lenvatinib for patients with von Hippel-Lindau disease-associated tumors or other specific solid tumors.

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium Czechia Denmark Finland France Germany +4